184 Chapter 7 136. Glaves, J. P., Primeau, J. O., Espinoza-Fonseca, L. M., Lemieux, M. J. & Young, H. S. The Phospholamban Pentamer Alters Function of the Sarcoplasmic Reticulum Calcium Pump SERCA. Biophys. J. 116, (2019). 137. Mark D. McCauley, X. H. T. W. Ryanodine Receptor Phosphorylation, Calcium/Calmodulin-dependent Protein Kinase II, and Life-threatening Ventricular Arrhythmias. Trends Cardiovasc. Med. 21, 48 (2011). 138. Kimura, Y., Kurzydlowski, K., Tada, M. & MacLennan, D. H. Phospholamban inhibitory function is activated by depolymerization. J. Biol. Chem. 272, 15061–15064 (1997). 139. Wittmann, T., Lohse, M. J. & Schmitt, J. P. Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers. J. Mol. Cell. Cardiol. 80, (2015). 140. DeWitt, M. M., MacLeod, H. M., Soliven, B. & McNally, E. M. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, (2006). 141. Koch, D. et al. Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers. Cell Rep. 36, 109448 (2021). 142. Kranias, E. G. & Hajjar, R. J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ. Res. 110, 1646–1660 (2012). 143. Haghighi, K., Bidwell, P. & Kranias, E. G. Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. J. Mol. Cell. Cardiol. 77, 160–167 (2014). 144. Kranias, E. G. & Hajjar, R. J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ. Res. 110, 1646–1660 (2012). 145. Vafiadaki, E., Haghighi, K., Arvanitis, D. A., Kranias, E. G. & Sanoudou, D. Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca Handling and Arrhythmogenesis. Int. J. Mol. Sci. 23, (2022). 146. Menzel, J. et al. 14-3-3 binding creates a memory of kinase action by stabilizing the modified state of phospholamban. Sci. Signal. 13, (2020). 147. Menzel, J. et al. 14-3-3 binding creates a memory of kinase action by stabilizing the modified state of phospholamban. Sci. Signal. 13, (2020). 148. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 149. Tarone, G. & Brancaccio, M. Keep your heart in shape: molecular chaperone networks for treating heart disease. Cardiovasc. Res. 102, 346–361 (2014). 150. Vasconcellos, L. R. C. et al. Protein aggregation as a cellular response to oxidative stress induced by heme and iron. Proc. Natl. Acad. Sci. U. S. A. 113, E7474–E7482 (2016). 151. Torres, M., Encina, G., Soto, C. & Hetz, C. Abnormal calcium homeostasis and protein folding stress at the ER: A common factor in familial and infectious prion disorders. Commun. Integr. Biol. 4, 258–261 (2011). 152. Soto, C. & Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21, 1332–1340 (2018). 153. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 154. Lin, J. H., Walter, P. & Benedict Yen, T. S. Endoplasmic Reticulum Stress in Disease Pathogenesis. Annual Review of Pathology: Mechanisms of Disease vol. 3 399–425 Preprint at https://doi.org/10.1146/annurev. pathmechdis.3.121806.151434 (2008). 155. Glick, D., Barth, S. & Macleod, K. F. Autophagy: cellular and molecular mechanisms. J. Pathol. 221, 3–12 (2010). 156. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 157. Te Rijdt, W. P. et al. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc. Pathol. 30, 23–26 (2017). 158. van der Klooster, Z. J. et al. P62-positive aggregates are homogenously distributed in the myocardium and associated with the type of mutation in genetic cardiomyopathy. J. Cell. Mol. Med. 25, (2021). 159. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020).
RkJQdWJsaXNoZXIy MTk4NDMw